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MORE ACCURATE DETERMINATION OF BLOOD VOLUME ALLOWS FOR
A HIGH CORRELATION OF PRE-APHERESIS PERIPHERAL BLOOD AND FI-
NAL APHERESIS PRODUCT CD34+ CELL COUNTS
Parker, B.1, Hastings, J.2, Folkert, J.2, Nagy, G.2, Bachier, C.1,
LeMaistre, C.F.1, Shaughnessy, P.J.1 1Texas Transplant Institute, San
Antonio, TX; 2Methodist Hospital, San Antonio, TX
The final apheresis product CD34+ cell count is used to determine
if more apheresis procedures are necessary to collect sufficient hema-
topoietic stem cells for autologous (auto) peripheral blood stem cell
transplantation. Flow cytometric analysis of CD34+ cells can take
several hours. A more timely way to predict apheresis product
CD34+ cell counts may help determine if further cytokines are nec-
essary or if apheresis catheters can be removed, and improve the ef-
ficiency of patient (pt) care. We performed a retrospective review of
all pts undergoing auto peripheral blood (PB) stem cell mobilization
with G-CSF alone, G-CSF and plerixafor, or with chemotherapy
(chemo) followed by G-CSF, from July 2010 through May 2011
who underwent PB stem cell collection on the COBE Spectra cell
separator. Linear regression models were used to formulate pt blood
volume (BV) based on the pre-apheresis CD34+ cell count per micro
liter of blood, the final apheresis product CD34+ cell counts, and the
amount of blood processed during the apheresis procedure. This cal-
culated BV is expressed by the formula BV5 82.5(pts weight in Kg)
+ 793.We then prospectively evaluated the next consecutive pts who
underwent stem cell mobilization and apheresis in June and July
2011. Twenty-seven apheresis collections were done on 26 pts.
The PB CD34+ cell count/ul was multiplied by 1000 and this prod-
uct was multiplied by the calculated BV and then divided by the pts
weight [(PBCD34+ cell count x 1000) x BV]/Kg to determine the
predicted apheresis product CD34+ cell count, which was then com-
pared to the actual apheresis product final CD34+ cell count. On the
first day of collection the mean for the predicted product CD34+ cell
count was 4.98 x 106 +/- 3.1 x 106, and the actual apheresis product
CD34+ cell count was 4.61 x 106 +/- 2.90 x 106 (Pearson correlation r
value of 0.913 and a p value\0.001). There was no significant differ-
ence in the correlation between pts mobilized with G-CSF alone, G-
CSF and plerixafor or after chemo and G-CSF. In conclusion,
a more accurate determination of pt BV allowed for a high degree
of correlation on the first day of PB stem cell collection between
the predicted product CD34+ cell count and the actual apheresis
product CD34+ cell count. An accurate prediction of the final apher-
esis product CD34+ cell count may allow for less cytokine use,
quicker removal of catheters, and more efficient disposition of
patients.155
CXCL12 G801A POLYMORPHISMS DO NOT PREDICT RESPONSE TO
MOBILIZATION BY PLERIXAFOR IN NORMAL ALLOGENEIC STEM CELL
DONORS
Schroeder, M.A.1, Rettig, M.P.1, Uy, G.L.1, Lopez, S.1, Trinkhaus, K.2,
Graubert, T.A.1, DiPersio, J.F.1 1Washington University School of Med-
icine, Saint Louis, MO; 2WashingtonUniversity School of Medicine, Saint
Louis, MO
Several reports suggest that G/A transition at position
801(G801A) in the 3’ untranslated region (3’UTR) of CXCL12 in
donors mobilized with G-CSF can predict for response to mobiliza-
tion. It is unknown if this polymorphism impacts mobilization with
the CXCR4 antagonist plerixafor. We hypothesized that the AA
polymorphism would show increased stem cell mobilization in re-
sponse to plerixafor.
Methods: A cohort of 55 donors enrolled in a phase I/II clinical trial
evaluating IV plerixafor mobilization were evaluated. 21 donors inthe phase I portion were mobilized with IV plerixafor at increasing
doses (0.08, 0.16, 0.24, 0.32, 0.40, 0.48mg/kg) in a 3+3 design fol-
lowed by one week wash out then mobilization and apheresis collec-
tionwith 0.32mg/kg subcutaneous plerixafor. 34 donors in the phase
II portion of the trial were mobilized with 0.32mg/kg plerixafor IV.
The G801A polymorphism in the 3’UTR of the CXCL12 gene was
analyzed in peripheral bloodmononuclear cells isolated from phase I
and II donors. Final collected CD34/Kg recipient weight on day 1,
CD34/liter apheresis on day 1, and reaching goal collection of
.2x10e6CD34/kg recipient weight were used as the dependent vari-
ables in determining mean differences based on genotype and for
univariate analysis.
Results: A total of 55 allogeneic donors were mobilized (female/
male 5 25/30; age range 12 – 67 years, median 50 years). In total
54 were evaluable for genotyping. The frequency of genotypes in
the combined cohort of 54 individuals was: GG 5 38(69.1%), AG
5 14(25.5%), AA 5 2(3.6%). There was no detectable difference
in themean number of CD34 cells/L apheresis on day 1 of collection
by CXCL12 genotype (p5 0.78, ANOVA, CD34/liter log10 scale).
Mean CD34 cells/L apheresis (log10 scale) was: GG 5 7.021 (95%
CI 6.936, 7.107), AG 5 7.028 (95%CI 6.883, 7.172), AA 5 6.892
(95%CI 6.524, 7.260). The probability of collecting at least
2x10e6 CD34 cells/Kg recipient weight on day 1 was not affected
by CXCL12 genotype (logistic regression, p 5 0.74). The propor-
tion of patients with a successful collection on day 1 in each group
was: GG 5 64.86 (95%CI 47.46, 79.79), AG 5 53.85 (95%CI
25.13, 80.78), AA 5 50 (95% CI 1.26, 98.74).
Conclusion: These results suggest that unlike what has been re-
ported for normal allogeneic stem cell donors mobilized with G-
CSF, plerixafor mobilization yield is not affected by the CXCL12
3’UTR G801A polymorphism.156
RELATIONSHIPS AMONG COMMONLY USED MEASURES OF CORD BLOOD
POTENCY, ALDHBR CELL CONTENT, AND COLONY FORMING CELL CON-
TENT IN CORDBLOODUNITS PRIOR TO CRYOPRESERVATION: TOWARDS
AN IMPROVED METRIC FOR POTENCY OF BANKED CORD BLOOD
Page, K.1, Betz-Stablein, B.2, Mendizabal, A.2, Wease, S.2, Shoulars, K.1,
Gentry, T.1, Balber, A.E.3, Kurtzberg, J.1 1Duke University, Durham,
NC; 2The EMMES Corporation, Rockville, MD; 3Cicada Biopharma-
ceutical Consulting, Durham, NC
Despite adequate total nucleated cell (TNC) dosing, engraft-
ment delays and failures remain a significant issue for patients un-
dergoing cord blood (CB) transplantation. We have shown before
that post-thaw colony forming units (CFU) better predicted en-
graftment compared to TNC and CD34+. However, the CFU as-
say is not standardized and results take weeks. Aldehyde
dehydrogenase (ALDH), an enzyme expressed in stem and pro-
genitor cells (ALDHbr cells), is detected by a rapid functional,
flow-based intracellular assay. In this study, we explored statistical
relationships among TNC, mononuclear cell count (MNC),
CD34+, ALDHbr cells and CFU in a large cohort of fresh CB
units (CBU) prior to cryopreservation. Our ultimate goal is to
identify the best parameter(s) to predict potency as defined by suc-
cessful engraftment.
Methods: Post-processed TNC, MNC, CD34+ and CFU content
were routinely enumerated on fresh CBUs donated to the Carolinas
Cord Blood Bank for public (n5 5268) or directed use (n5 14) from
9/07-7/09. Aldecount (Aldagen, Inc) was used to measure
ALDHbr content. Statistical relationships were established.
Results: The median TNC, CD34+, MNC, ALDHbr and CFU
content were: 11.8x108(range, 2.9-55.5x108), 3.36 x106(range,
0.17-98.2x106), 5.5x108(range, 1.7-20.0x108), 4.3x 106(0-36.6x106)
and 34.0x105(range, 0.6-193.3x105), respectively. Significant corre-
lations existed among measured parameters (Table 1). By stan-
dardizing univariate models, we were able to rank using AIC values.
CFUwas best predicted byTNC (AIC5 11,501) followed closely by
ALDHbr (AIC 5 12,012) and, to a lesser degree, MNC (AIC 5
12,412) and CD34+ (AIC 5 12,612). Multivariate results were
similar (data not shown). Ratios of ALDHbr and CD34+ to CFU
were 1.36:1 and 1.09:1, respectively, whereas the ratio of TNC to
CFU was 332:1.
S262 Poster Session ITable 1. Correlation coefficients for parameters measured on
fresh cord blood (all p<0.0001).
TNC CFU MNC ALDHbr CD34TNC 1.00 0.70 0.82 0.58 0.50
CFU 0.70 1.00 0.61 0.66 0.60
MNC 0.82 0.61 1.00 0.47 0.41ALDHbr 0.58 0.66 0.47 1.00 0.70
CD34+ 0.50 0.60 0.41 0.70 1.00Conclusions: In this large cohort, measured fresh CB parameters
correlated well and predicted each other. Furthermore, ALDHbr
correlated well with CFUs and is a promising surrogate for CFUs
as a potency assay given the technical difficulties with the CFU assay.
In fresh CB, ALDHbr content was modestly more reliable in pre-
dicting CFUs than CD34+. We and others have shown before that
cells survive freezing and thawing with different efficiencies. We
continue to study which parameters, individually or combined, cor-
relate best with engraftment when measured on attached CBU seg-
ment or after unit thaw in order to improve potency assessment
during the final stages of donor selection.
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CYCLOPHOSPHAMIDE PRIMING WITH INTRAVENOUS PLERIXAFOR AND
GCSF MOBILIZATION FOR MULTIPLE MYELOMA
Krishnan, A.1, Wang, S.1, Htut, M.1, Farol, L.2, Palmer, J.3, Quazi, I.3,
Forman, S.1, Tsai, N.1, Forman, S.1 1City of Hope Cancer Center,
Duarte, CA; 2Southern CA Kaiser/City of Hope, Duarte, CA; 3City of
Hope, Duarte, CA
Background: Plerixafor (Pl), an inhibitor of CXCR4 has been ap-
proved for use with G-CSF for stem cell mobilization for autologous
transplant in patients withmultiplemyeloma and non-Hodgkin lym-
phoma. However, the subcutaneous route of injection necessitates
dosing 11 hours prior to apheresis. Intravenous (IV) dosing may re-
sult in a faster peak CD34+ cell count allowingmore convenient dos-
ing. Other strategies to increase stem cell yield include
chemotherapy mobilization with cyclophosphamide (CY). Herein
we report on the use of CY followed by intravenous Pl plus G-CSF.
Methods: The primary objectives were safety and efficacy of intra-
venous administration of Pl following CY mobilization in pts with
myeloma. The secondary endpoint was the ability to collect .5 x
106 CD34+ cells/kg in two or fewer days. Patients received CY
1.5g/m2 followed byG-CSF (10mg/kg) 24 hrs post chemo. Apheresis
commenced 10 days post CY, Pl IV (0.16-0.24mg/kg) was given on
the morning of apheresis, 4-6 hrs prior to apheresis. Peripheral
CD34+ cell counts were drawn just before Pl administration and at
1- 4 hr time points post.
Results: Eleven patients have been enrolled to date and are available
for analysis;median age is 59.2 (range: 43.4 – 68.9) years, median no. of
prior therapies is 1 (range: 1-3). Three pts were treated with 0.16mg/
kg, 8 with 0.24mg/kg of Pl. Eight patients had prior lenalidomide and
9 had prior bortezomib. Disease status at entry was 2 CR, 1MR, 6 PR
and 2 VGPR. CD34 counts increased a median of 1.8 fold (range: 1.1-
2.9) 1 hr post the first IV dose.
Seven of eleven pts met the secondary endpoint. Nine pts have been
transplanted and all engrafted at a median of 11 days (range 10-12) for
neutrophil engraftment and 16 days for plts (range 8-22). Grade 3/4
non heme toxicities occurred in ten pts and included emesis, anorexia,
hyperglycemia, hyperuricemia, hyponatremia and bone pain.
Conclusions: The adverse event profile and efficacy of IV Pl post
chemotherapy is similar to subcutaneous administration, with the ex-
ception of chemo related toxicities and allows for same day dosing of
Pl as apheresis.158
HIGH-RESOLUTION MULTIDIMENSIONAL PROTEOMIC ANALYSIS OF
CIRCULATING BIOMARKERS IN PATIENTS WITH ACUTE GRAFT-VER-
SUS-HOST DISEASE (aGVHD)
Lemos, G.1,5, Pizzatti, L.1,3,4,5, Pinto, D.O.1,4, Bouzas, L.F.2,5,
Abdelhay, E.1,3,5 1Bone Marrow Transplantation Unit (CEMO) -INCA, Rio de Janeiro, Brazil; 2Bone Marrow Transplantation Unit
(CEMO) - INCA, Rio de Janeiro, Brazil; 3Proteomics Network of Rio
de Janeiro, Rio de Janeiro, Brazil; 4Sociedade Beneficente Israelita Brasi-
leira Hospital Albert Einstein, Sao Paulo, Brazil; 5National Cancer Insti-
tute (INCA), Rio de Janeiro, Brazil
Introduction:The graft-versus-host disease is a serious complication
of allogeneic hematopoietic stem cells transplantation (HSCTs) and
the major cause of morbidity and mortality in patients undergoing
this therapy. The diagnosis of aGVHD is still carried out by clinical
observations followed by biopsies of injured organs. Thus, studies
that aim to identify potential biomarkers for aGVHD are needed.
Multidimensional proteomic strategies on a large scale have been
widely used for the identification and quantification of biomarkers in
different diseases. Therefore the identification and absolute quantifi-
cation of proteins and peptides differentially expressed in the plasma
of patients who developed aGVHD, is extremely important.
Objective: Compare and quantify the protein expression profile of
the patients plasma after allogeneic HSCT comparing patients
who developed aGVHD with those that did not develop aGVHD
and the plasma of healthy donors.
Materials and Methods: This study analyzed 73 plasma samples of
patients who underwent allogeneic HSCT at D+45 and 50 plasma
samples from healthy donors. 31 samples had acute myeloid leuke-
mia (AML) as underlying disease, 21 patients developed aGVHD
and 10 patients did not develop aGVHD. 42 patients had as under-
lying disease acute lymphoblastic leukemia (ALL), 24 and 18 devel-
oped aGVHDor did not develop aGVHD respectively. The samples
were concentrated 16x with 3k Amicon columns (Millipore) and
digested in solution and analyzed bymultidimensional chromatogra-
phy (MudPIT) in mass spectrometry-2D-NanoESI MSE (MudPIT)
using Synapt HDMS mass spectrometer (Waters). The proteins
were identified and quantified using the software Proteinlynks
Global Server (Waters) with the tool Expression E.
Results and Conclusions: We identified 99 and 109 proteins in
AML and ALL respectively. Differential expression analysis identified
102 proteins between the pools of samples compared. Among the pro-
teins identified protein NALP2 stands out as a possible biomarker of
aGVHD in patients who had AML as the underlying disease.
Financial Support: INCA /Ministry of Health / CNPq / FINEP.159
IMPACT OF GRAFT CD34 CELL DOSE ON CHRONIC GRAFT-VERSUS-HOST
DISEASE (cGVHD) AND PREDICTIVE VALUES OF CD3 CELL DOSE AND
DAY 56 CHIMERISM ON SURVIVAL IN NONMYELOABLATIVE (NMA) AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Pecheux, L., Ahmad, I., Baron, C., Busque, L., Cohen, S., Kiss, T.,
Roy, D.-C., Roy, J., Sauvageau, G., Lachance, S. Ho^pitalMaisonneuve-R-
osemont, Montreal, QC, Canada
Purpose:Compared tomyeloablative regimensNMAHSCT is asso-
ciated with decreased toxicity but higher incidence of cGVHD and re-
lapse. The optimalCD34+ cell dose inNMAHSCTand the impact of
graft composition on transplant outcome remains controversial.
We studied the influence of graft composition, engraftment kinet-
ics and post-transplant chimerism on outcomes in this setting.
Methods: We retrospectively analyzed graft composition and chi-
merism data in a homogenous cohort of 81 consecutive patients
treated for multiple myeloma with HLA-matched sibling NMA
HSCTafter a conditioning regimen based on FluCy. All patients un-
derwent an autologous followed by a NMA allogeneic HSCT in
a tandem approach. GVHD prophylaxis combined tacrolimus and
mycophenolate mofetil (MMF). MMF was stopped at day +50 and
tacrolimus tapered between day+80 and day+100. FDC was defined
as . 5 95% donor CD3 circulating cells.
Results: Progression-free (PFS) and overall survival (OS) at 8 years
was respectively 42,7% and 70.7%. All but 8 patients achieved FDC
at day 180. Median time from transplantation to FDC was 120 days.
Four out of the 8 patients with persistent mixed chimerism (MC) ex-
perienced progression, 2 of them before day 100. Graft composition
in CD3 and CD34 cells were correlated (r 5 0.291, P 5 0.009).
CD34 \ 5 x10^6/kg was associated with less cGVHD (73% vs
92% p 5 0,039). CD3\ 25 x10^7/kg was associated with better
